SER-155 is an oral, 16-strain microbiome therapeutic that works by decolonizing gastrointestinal pathogens, strengthening the epithelial barrier, and inducing immune tolerance.
The Asia-Pacific hospital-acquired infection diagnostics market accounted for $418.937 million in 2019, and is expected to reach $780.882 million by 2027, registering a CAGR of 7.5% from 2020 to 2027.
At airports, frequently disinfecting surfaces, mask-wearing and antimicrobial surface coatings can all help prevent the spread of norovirus, according to a new study.